Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) just unveiled an announcement.
Shanghai Fosun Pharmaceutical’s subsidiary, Fosun Wanbang, has received approval from the National Medical Products Administration for a clinical trial of Foritinib Succinate Capsules. This new drug is intended for the adjuvant treatment of non-small cell lung cancer with specific genetic markers and marks a significant step in the company’s ongoing efforts to expand its oncology portfolio.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$17.20 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company incorporated in China, operating in the pharmaceutical industry. The company focuses on developing and manufacturing a range of pharmaceutical products, with a particular emphasis on innovative chemical drugs for various medical conditions.
YTD Price Performance: 74.45%
Average Trading Volume: 10,971,479
Technical Sentiment Signal: Buy
Current Market Cap: HK$83.17B
For detailed information about 2196 stock, go to TipRanks’ Stock Analysis page.